PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision repair, may correlate with clinical response to platinum agents. We found that most primary lung tumor specimens demonstrated a stronger protein expression of poly (adenosine diphosphate ribose) polymerases 1 (PARP1) than their normal counterparts. Therefore, we hypothesized that combining PARP inhibition with platinum compounds may be an approach to improve platinum-based therapy for NSCLC. Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model. Furthermore, mechanistic studies indicated that combined PARP inhibitor and cisplatin could lead to sustained DNA double-strand breaks, prolonged G2/M cell cycle arrest with distinct activation of checkpoint kinase 1 signaling and more pronounced apoptosis preferentially in lung cancer cells with low ERCC1 expression. Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188 · cited 1×
“Clonogenic survival was assayed as described previously (24).”
MethodCellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801 · cited 1×
“Platinum–DNA adducts are removed mainly by the nucleotide excision repair (NER) pathway (3).”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“Phase II clinical trials further demonstrated the efficacy and safety of olaparib in BRCA-associated breast and ovarian cancers (17,18).”
BackgroundOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“Moreover, a recent randomized phase II study demonstrated that maintenance therapy with olaparib could provide a significant improvement in progression-free survival in patients with platinumsensitive relapsed serous ovarian cancer (19).”
BackgroundDNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727 · cited 1×
“When evaluated in clinical trials, the International Adjuvant Lung Cancer Trial demonstrated that only ERCC1 low/negative but not ERCC1 high/positive tumors had a survival benefit from cisplatin-based adjuvant chemotherapy (7).”
MethodTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · cited 1×
“Inhibition of poly (adenosine diphosphate ribose) polymerases (PARPs), key components of base excision repair, have been shown to enhance platinum sensitivity in BRCA-associated breast and ovarian cancers (11,12).”
BackgroundThe ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276 · cited 2×
“We then examined the ATR-CHK1 and ATM-CHK2 pathways, which are two principal mechanisms activated by DNA damage and their activation is involved in regulating cell cycle arrest in late G1, intra-S and G2 phases (32).”
BackgroundMethod
Research works printed but not linked: 3
- KIRSCHNER, 2010, Anticancer Research, 30, 3223
- Selvakumaran, 2003, Cancer Research, 63, 1311
- Sorenson, 1988, Cancer Research, 48, 6703
Cited by
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
“Combination strategies with olaparib and chemotherapeutic agents have shown to be effective in ERCC1 or PTEN-deficient lung cancer cells, showing that other deficiencies in DNA-repair pathways frequently occurring in NSCLC might have an impact on the response to olaparib treatment, and consequently also on this combin…”
BackgroundTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
“Early preclinical data has found PARP inhibition sensitized SCLC to cisplatin therapy (67).”
BackgroundDrugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D., Lee, S.-H., Williamson, E. A., & Hromas, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 159
Metadata
- Authors
- Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Mount Sinai Hospital (US)
- Columbia University Irving Medical Center (US)
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-28
- Volume
- 34
- Issue
- 4
- Pages
- 739-749
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- PMC
- PMC3616665
- OpenAlex
- W2135915034
- Cited by
- 99
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 18 · 2020: 4 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 3
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Carcinogenesis (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health (5k12ca132783-12)
- National Cancer Institute (CA 130536, 5K12CA132783-04, R01CA130536)
- National Institute of General Medical Sciences (R01GM079107, GM079107)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibition, cisplatin, ERCC1, non-small cell lung cancer, olaparib, veliparib, nucleotide excision repair, drug synergy, DNA double-strand breaks, G2/M cell cycle arrest, apoptosis, tumor markers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Checkpoint Kinase 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Cisplatin, DNA-Binding Proteins, Drug Synergism, Endonucleases, Humans, Lung Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Kinases, Apoptosis, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, DNA Breaks, Double-Stranded, G2 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. https://app.cochat.ai/papers/10.1093/carcin/bgs393
- The paper
- Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013). PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. https://doi.org/10.1093/carcin/bgs393
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.